<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar1988</article-id><article-id pub-id-type="pmid">16805919</article-id><article-id pub-id-type="doi">10.1186/ar1988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Lopez-Larrea</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>inmuno@hca.es</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Blanco-Gelaz</surname><given-names>Miguel Angel</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Torre-Alonso</surname><given-names>Juan Carlos</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Armas</surname><given-names>Jacome Bruges</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Suarez-Alvarez</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A6" contrib-type="author"><name><surname>Pruneda</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A7" contrib-type="author"><name><surname>Couto</surname><given-names>Ana Rita</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A8" contrib-type="author"><name><surname>Gonzalez</surname><given-names>Segundo</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A9" contrib-type="author"><name><surname>Lopez-V&#x000e1;zquez</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A10" contrib-type="author"><name><surname>Martinez-Borra</surname><given-names>Jesus</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mtnezborra@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Histocompatibility and Transplantation Unit, Hospital Universtario Central de Asturias, Celestino Villamil s/n. 33006 Oviedo, Asturias, Spain</aff><aff id="I2"><label>2</label>Rheumatology Unit, Hospital Monte Naranco, Avda Dres Fernandez Vega 107. 33012 Oviedo, Asturias, Spain</aff><aff id="I3"><label>3</label>Immunogenetic Service, Hospital de Santo Espirito de Angra do Heroismo, Vinha Brava. 9700 Angra do Heroismo, Azores, Portugal</aff><aff id="I4"><label>4</label>Functional Biology Department, University of Oviedo, Avda Julian Claveria s/n. 33006 Oviedo, Asturias, Spain</aff><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2006</year></pub-date><volume>8</volume><issue>4</issue><fpage>R101</fpage><lpage>R101</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/8/4/R101"/><history><date date-type="received"><day>10</day><month>3</month><year>2006</year></date><date date-type="rev-request"><day>23</day><month>3</month><year>2006</year></date><date date-type="rev-recd"><day>5</day><month>4</month><year>2006</year></date><date date-type="accepted"><day>5</day><month>6</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 L&#x000f3;pez-Larrea et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>L&#x000f3;pez-Larrea et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Lopez-Larrea Carlos inmuno@hca.es </dc:author><dc:title> Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Arthritis Research &#x00026; Therapy 8(4): R101-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1478-6354(2006)8:4&#x0003c;R101&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1478-6354</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Killer cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) loci are both highly polymorphic, and some HLA class I molecules bind and trigger cell-surface receptors specified by <italic>KIR </italic>genes. We examined whether the combination of <italic>KIR3DS1</italic>/<italic>3DL1 </italic>genes in concert with HLA-B27 genotypes is associated with susceptibility to ankylosing spondylitis (AS). Two HLA-B27-positive Caucasian populations were selected, one from Spain (71 patients and 105 controls) and another from the Azores (Portugal) (55 patients and 75 controls). All were typed for HLA-B and <italic>KIR </italic>(<italic>3DS1 </italic>and <italic>3DL1</italic>) genes. Our results show that in addition to B27, the allele <italic>3DS1 </italic>is associated with AS compared with B27 controls (<italic>p </italic>&#x0003c; 0.0001 and <italic>p </italic>&#x0003c; 0.003 in the Spanish population and Azoreans, respectively). We also observed that the association of KIR3DS1 to AS was found in combination with HLA-B alleles carrying Bw4-I80 in trans position in the Spanish population (30.9% in AS versus 15.2% in B27 controls, <italic>p </italic>= 0.02, odds ratio (OR) = 2.49) and in Azoreans (27.2% in AS versus 8.7% in B27 controls, <italic>p </italic>= 0.01, OR = 4.4 in Azoreans). On the other hand, 3DL1 was decreased in patients compared with B27 controls (<italic>p </italic>&#x0003c; 0.0001 in the Spanish population and <italic>p </italic>&#x0003c; 0.003 in Azoreans). The presence of this allele in combination with Bw4-I80 had a protective effect against the development of AS in the Spanish population (19.7% in AS, 35.2% in B27 controls; <italic>p </italic>= 0.03, OR = 0.45). The presence of <italic>KIR3DS1 </italic>or <italic>KIR3DL1 </italic>in combination with HLA-B*27s/HLA-B Bw4-I80 genotypes may modulate the development of AS. The susceptibility to AS could be determined by the overall balance of activating and inhibitory composite <italic>KIR</italic>-HLA genotypes.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>The association of ankylosing spondylitis (AS) with human leukocyte antigen (HLA)-B27 has been demonstrated worldwide, and evidence for the role of HLA-B27 in AS comes from linkage and association studies in humans and transgenic animal models. However, twin studies indicate that HLA-B27 contributes only 16% of the total genetic risk for disease [<xref ref-type="bibr" rid="B1">1</xref>]. Genome-wide scans have implicated regions on chromosomes 2q, 6p, 6q, 10q, 11q, 16q, 17q, and 19q in AS [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. The killer immunoglobulin-like receptor (KIR) genes encode a group of proteins that are expressed on natural killer (NK) cells and in some T cells that are located on chromosome 19q13.4 in the leukocyte receptor complex (reviewed in [<xref ref-type="bibr" rid="B4">4</xref>]). KIR proteins act as receptors that recognise major histocompatibility complex (MHC) class I molecules and are directly involved in the activation and inhibition of NK and possibly also in CD8<sup>+ </sup>T cells [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Given the receptor-ligand relationship between certain combinations of KIR and HLA class I molecules, it is reasonable to hypothesise a synergistic relationship between these polymorphic loci. This could be the case of the KIR3DL1 inhibitory receptor, the only KIR known to recognise HLA-B alleles. It binds to HLA-B with serological-defined epitope Bw4 (determined by amino acid positions 79&#x02013;83 of the molecule) [<xref ref-type="bibr" rid="B7">7</xref>] with an isoleucine at position 80 (Bw4-I80) [<xref ref-type="bibr" rid="B8">8</xref>]. The interaction of KIR3DL1 and Bw4-I80 has an inhibitory effect on the cytotoxic capacity of NK cells. All HLA-B27 subtypes carry Bw4 epitope, with the exception of B*2708 and other related subtypes, which carry Bw6. From those with Bw4, B*2702 is the only subtype with an isoleucine at position 80 (Bw4-I80). The differences between the activating receptor KIR3DS1 and the inhibitory 3DL1 are located in the intracytoplasmic tail. The inhibitory receptor has a long tail containing immunoreceptor tyrosine inhibitory motifs, whereas the activating receptor has a short tail without this motif but with the capacity to interact with activating adaptor proteins such as DAP12 [<xref ref-type="bibr" rid="B9">9</xref>]. The ligand for KIR3DS1 has not been determined, although it has been shown that the KIR3DS1 activating receptor in combination with HLA-B alleles that encode molecules with isoleucine at position 80 (HLA-B Bw4-I80) results in delayed progression to AIDS after HIV-1 infection [<xref ref-type="bibr" rid="B10">10</xref>]. Recent studies have also reported a strong association of KIR/HLA combinations in the development of psoriatic arthritis [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>The aim of this study was to analyse whether <italic>KIR3DL1 </italic>and <italic>3DS1 </italic>genes, and their possible synergistic effect with HLA-B alleles, influence the susceptibility to AS in HLA-B27-positive individuals.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients and controls</title><p>Two B27-positive Caucasians populations were selected for this study, one from Spain (71 patients with AS and 105 healthy matched controls) and another from the Azores (Portugal) (55 patients with AS and 57 healthy matched controls). The patients with AS were diagnosed at the rheumatology units of the Hospital Universtario Central de Asturias and Hospital Naranco, Oviedo, Asturias, Spain, and the Rheumatic Diseases Clinic of the Angra do Heroismo Hospital, Azores, in accordance with New York criteria [<xref ref-type="bibr" rid="B12">12</xref>]. Radiographs of the pelvis and lumbar spine were obtained in all patients. Sacroiliac joint changes were determined on the basis of the New York criteria. All patients had sacroiliitis bilateral grade II or more. Both patients and controls gave written informed consent prior to enrolling in the study. The protocol was approved by the ethics committees of our hospitals and conducted according to the Declaration of Helsinki.</p><p>B27 subtypes were determined by polymerase chain reaction (PCR) using sequence-specific primer (SSP) as described previously [<xref ref-type="bibr" rid="B13">13</xref>]. HLA-B alleles and Bw4 and Bw6 epitopes were typed by PCR-sequence-specific oligoprobes (SSOs) with RELI&#x02122;-SSO typing kits (Dynal Biotech, Oslo, Norway). <italic>KIR3DL1 </italic>and <italic>3DS1 </italic>genotyping was performed by PCR with gene-specific primer pairs in accordance with the method previously described [<xref ref-type="bibr" rid="B14">14</xref>]. Both were considered as alleles from the same locus.</p><p>Allelic frequencies were calculated by direct counting, and the significance of the association was determined using the &#x003c7;<sup>2 </sup>test with Yate's correction or Fisher's exact test. The odds ratio (OR) was calculated by the cross-product ratio. Exact confidence intervals of 95% were obtained. The &#x003c7;<sup>2 </sup>test was used for Hardy-Weinberg equilibrium (HWE) by comparing the observed number of subjects for each genotype with the expected number of subjects, assuming the existence of HWE.</p></sec></sec><sec><title>Results and Discussion</title><p>Here, we have analysed the possible influence of KIR genotypes in the susceptibility to AS in B27 individuals. The study was undertaken in two genetically distinct Caucasian populations but with a slightly different distribution of B27 alleles [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>].</p><p>HLA-B27 represents a family of at least 27 closely related alleles (B*2701-27) that differ in their ethnic distribution. We used an SSP typing approach (PCR-SSP) capable of allelic detection of all B27 alleles described at present. The B27 alleles detected in our study can be classified into two categories: one group of alleles over-represented (B*2705, 02) and another group of alleles with minor representation such as B*2703, B*2707, B*2708, and B*2713. No differences were found in the distribution of B27 subtypes among patients with AS and B27-positive matched controls in either the Spanish or Azorean populations. We found some alleles that are present only in the Azorean population, such as B*2703 and B*2708, whereas we only found one individual with B*2713 in the Spanish population (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>However, differences in the distribution of the <italic>KIR3DS1 </italic>allele were found among these groups in both populations (Table <xref ref-type="table" rid="T2">2</xref>). This allele was over-represented in the AS group compared with B27-positive healthy controls (42.9% versus 22.3%, <italic>p </italic>&#x0003c; 0.0001, OR = 2.6 in the Spanish population and 35.4% versus 17.5%, <italic>p </italic>&#x0003c; 0.003, OR = 2.58 in Azoreans). We also found a different distribution of the <italic>KIR3DL1 </italic>frequency among the groups because this gene and <italic>KIR3DS1 </italic>segregate as alleles. <italic>KIR3DL1 </italic>was found to be decreased in patients with AS compared with B27-positive controls (57% versus 77.6%, <italic>p </italic>&#x0003c; 0.0001, OR = 0.3 in the Spanish population and 64.5% versus 82.4%, <italic>p </italic>&#x0003c; 0.003, OR = 0.38 in Azoreans). Both alleles were also distributed differently when we considered the homozygous genotypes. <italic>3DL1</italic>/<italic>3DL1 </italic>was increased in B27-positive controls (<italic>p </italic>= 0.0008, OR = 0.33 in the Spanish population and <italic>p </italic>&#x0003c; 0.001, OR = 0.26 in Azoreans) compared with patients with AS. On the other hand, the <italic>3DS1</italic>/<italic>3DS1 </italic>genotype was increased in patients with AS compared with B27 controls, although in the Azorean population this was not significant with the size of the sample studied (<italic>p </italic>= 0.0009, OR = 3.75 in the Spanish population). When both genotypes are present (<italic>3DS1</italic>/<italic>3DL1</italic>), the activating effect appears to be prevailing and so this genotype is increased in patients in both populations, significantly in Azoreans (<italic>p </italic>= 0.005). No deviation from the HWE was detected in either patients or controls.</p><p>Finally, we analysed whether the Bw4-I80 ligand is involved in the susceptibility of <italic>KIR3DS1 </italic>to AS. We classified the HLA-B alleles of the subjects studied according to the presence of Bw4/Bw6 serological epitopes. The incidence of the B27 genotypes with HLA-B alleles in <italic>trans</italic> position with a Bw4-I80 (or in <italic>cis</italic> when the allele is B*2702) was not found to be different in patients with AS and both control groups. However, we found these two factors to be combined (3DS1/B27 genotypes with Bw4-I80 in trans) in 30.95% of patients with AS and in only 15.2% of B27-positive controls in the Spanish population (<italic>p </italic>= 0.02, OR = 2.49) and in 27.2% of patients with AS and in 8.7% of B27-positive controls in Azoreans (<italic>p </italic>= 0.01, OR = 4.4). Moreover, the inhibitory 3DL1/Bw4-I80 genotype was found to be increased in the control group compared with patients with AS in both populations, although not significantly in the Azorean population, possibly due to the size of the population.</p><p>Thus, the attributable effect of <italic>KIR3DL1 </italic>(protection) or <italic>3DS1 </italic>(susceptibility) on AS susceptibility may be more effective when the corresponding ligand Bw4-I80 is present and the effects could be additional to the presence of HLA-B*27. The presence of one single additional HLA-B allele carrying the Bw4-I80 epitope in B*27-positive individuals could modulate the state of cell activation of NK (and/or T) cells in conjunction with the pattern of <italic>KIR </italic>gene expression.</p><p><italic>KIR3DL1 </italic>and <italic>3DS1 </italic>genes are polymorphic, and in the case of <italic>KIR3DL1 </italic>it has been described that this polymorphism may influence the expression [<xref ref-type="bibr" rid="B17">17</xref>] or the inhibitory effect [<xref ref-type="bibr" rid="B18">18</xref>] of the different alleles. This fact could also be important for the role of these genes in the susceptibility to AS.</p><p>The mechanism by which HLA-B27 confers susceptibility to inflammatory AS is not understood but is presumed to involve some unique aspect of its role in antigen presentation (reviewed in [<xref ref-type="bibr" rid="B19">19</xref>]). It has been argued that the T-cell response to an arthritogenic peptide(s) of endogenous origin and bound by HLA-B27 molecules might be the cause of spondyloarthropathies. In addition to their classical antigen-presenting role, it has been described that HLA-B27 are recognised by members of the KIR and leukocyte immunoglobulin-like receptor (ILT) families in both human and animal models. Members of KIR (3DL1 and 3DL2) and ILT (ILT4) are able to bind B27 in both classical &#x003b2;2m/heavy chain (HC) and &#x003b2;2m-free HC homodimers (HC-B27) that are dependent on the presence of Cys67 of the B27 molecule [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. It has been argued that alternative recognition of different forms of HLA-B27 by KIR or ILT could influence their immunomodulatory function and may imply a role in inflammatory disease.</p><p>Binding of the KIR3DL1 receptor to the Bw4 family of MHC class I receptors has been shown to be dependent on key residues of the HC around isoleucine 80 [<xref ref-type="bibr" rid="B8">8</xref>]. However, it has been described that HLA-B*2705, which carries a Bw4 epitope containing threonine at residue 80, is also recognised by KIR3DL1, this interaction being peptide-specific [<xref ref-type="bibr" rid="B23">23</xref>]. In fact, it has been shown that KIR3DL1 recognises HLA-B27 molecules when loaded with a self-peptide and with a number of viral non-self-peptides. Nevertheless, some viral peptides such as EBV EBNA3C 258&#x02013;266, which bind to HLA-B*2705, block the NK inhibitory receptor 3DL1 [<xref ref-type="bibr" rid="B24">24</xref>]. Anchor residues at position P7 and P8 of some viral peptides may prevent KIR3DL1-mediated recognition of HLA-B27. Similarly, it is probable that a significant fraction of B*27 'arthritogenic' ligands fail to interact with KIR3DL1 during the course of microbial infection, which thereby influences the activation of activating NK receptors (NKRs) (3DS1 and others) and subsequent progression to AS. It is therefore plausible that the presence of another HLA-B allele carrying the Bw4-I80 epitope may antagonise the unfavourable interaction of KIR3DL1 with an HLA-B27-peptide.</p><p>NKRs are expressed on subsets of effector and memory T cells [<xref ref-type="bibr" rid="B25">25</xref>]. It has previously been shown that stimulatory KIRs are able to promote proliferative responses of CD28<sup>null </sup>T-cell clones, suggesting that the recognition of self-MHC class I molecules may lead to clonal expansion [<xref ref-type="bibr" rid="B26">26</xref>]. In a similar way to CD28, KIR receptors may function as T-cell receptor (TCR) co-stimulatory molecules. Interestingly, circulating effectors of CD4<sup>+</sup>CD28<sup>null </sup>and CD8<sup>+</sup>CD28<sup>null </sup>T cells were found to be expanded in AS and associated with more severe joint restrictions [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Expression of NKRs, including various members of the KIR family, was found on CD4<sup>+</sup>CD28<sup>null </sup>T cells in patients with AS, and this resembles that found in rheumatoid arthritis [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>].</p><p>The existence of a high degree of heterogeneity has been described in the expression of NKR by intrasynovial CD8<sup>+ </sup>T cells that could modulate their cytotoxicity and play a role in the control of this HLA class I-associated autoimmune disease [<xref ref-type="bibr" rid="B31">31</xref>]. The activating KIR3DS1 in CD28<sup>null</sup>T cells could provide a mechanism through which TCR could be involved in enhancing and extending the immune response in AS, lowering the activation threshold for these cells, irrespective of their antigen specificity. The expression of KIR3DL1 may serve as a mechanism to control the activity of self-reactive T cells induced by arthritogenic peptides presented by &#x003b2;2m/HC or HC-B27, thus mediating T-cell tolerance to self-antigens. The genetic imbalance between KIR and their HLA class I ligands may enhance the activation of T cells with a low affinity for joint self-antigens, thereby contributing to the pathogenesis of AS.</p></sec><sec><title>Conclusion</title><p>The presence of <italic>KIR3DS1 </italic>or <italic>KIR3DL1 </italic>in combination with HLA-B*27s/HLA-B Bw4-I80 genotypes may modulate the development of AS. The susceptibility to AS could be determined by the overall balance of activating and inhibitory composite <italic>KIR</italic>-HLA genotypes. Further analysis of NKR expression on T cells in patients with AS may help to elucidate the role of KIR receptor in predisposing to disease.</p></sec><sec><title>Abbreviations</title><p>AS = ankylosing spondylitis; HC = heavy chain; HLA = human leukocyte antigen; HWE = Hardy-Weinberg equilibrium; ILT = immunoglobulin-like lymphocyte T receptors; KIR = killer cell immunoglobulin-like receptor; MHC = major histocompatibility complex; NK = natural killer; NKR = natural killer receptor; OR = odds ratio; PCR = polymerase chain reaction; SSO = sequence-specific oligoprobe; SSP = sequence-specific primer; TCR = T-cell receptor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CL conceived the study, participated in its design and coordination, and helped to draft the manuscript. JCT and JBA participated in the design of the study and in the selection of the patients. MAB, BS, LP, and ARC carried out the molecular genetic studies. SG participated in drafting the manuscript. AL participated in the design of the study and performed the statistical analysis. JM participated in the design of the study, carried out the molecular genetic studies, and participated in the statistical analysis. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported in part by the Spanish Ministry of Education and Science (grant SAF2004-02669). JM was supported in part by the Spanish Post-MIR program from 'Fondo de Investigaci&#x000f3;n Sanitaria'. We thank David H. Wallace for critical revision of the manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>AM</given-names></name><name><surname>Wordsworth</surname><given-names>BP</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name></person-group><article-title>Genetic susceptibility to ankylosing spondylitis</article-title><source>Curr Mol Med</source><year>2004</year><volume>4</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15011955</pub-id><pub-id pub-id-type="doi">10.2174/1566524043479284</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Pile</surname><given-names>KD</given-names></name><name><surname>Kennedy</surname><given-names>LG</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Andrew</surname><given-names>L</given-names></name><name><surname>March</surname><given-names>R</given-names></name><name><surname>Shatford</surname><given-names>JL</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Wordsworth</surname><given-names>BP</given-names></name></person-group><article-title>A genome-wide screen for susceptibility loci in ankylosing spondylitis</article-title><source>Arthritis Rheum</source><year>1998</year><volume>41</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">9550467</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199804)41:4&#x0003c;588::AID-ART5&#x0003e;3.0.CO;2-0</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laval</surname><given-names>SH</given-names></name><name><surname>Timms</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Bradbury</surname><given-names>L</given-names></name><name><surname>Brophy</surname><given-names>S</given-names></name><name><surname>Milicic</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>L</given-names></name><name><surname>Siminovitch</surname><given-names>KA</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>918</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">11231900</pub-id><pub-id pub-id-type="doi">10.1086/319509</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilches</surname><given-names>C</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>KIR: diverse, rapidly evolving receptors of innate and adaptive immunity</article-title><source>Annu Rev Immunol</source><year>2002</year><volume>20</volume><fpage>217</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">11861603</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.092501.134942</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><article-title>Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">8760835</pub-id><pub-id pub-id-type="doi">10.1084/jem.184.2.789</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Anfossi</surname><given-names>N</given-names></name></person-group><article-title>Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">15039756</pub-id><pub-id pub-id-type="doi">10.1038/nri1306</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gumperz</surname><given-names>JE</given-names></name><name><surname>Litwin</surname><given-names>V</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor</article-title><source>J Exp Med</source><year>1995</year><volume>181</volume><fpage>1133</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">7532677</pub-id><pub-id pub-id-type="doi">10.1084/jem.181.3.1133</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Longo</surname><given-names>A</given-names></name><name><surname>Ferrara</surname><given-names>GB</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80</article-title><source>J Exp Med</source><year>1994</year><volume>180</volume><fpage>1235</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">7931060</pub-id><pub-id pub-id-type="doi">10.1084/jem.180.4.1235</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Corliss</surname><given-names>BC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Leong</surname><given-names>C</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name></person-group><article-title>Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells</article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">9490415</pub-id><pub-id pub-id-type="doi">10.1038/35642</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Nelson</surname><given-names>GW</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>Buchbinder</surname><given-names>S</given-names></name><name><surname>Hoots</surname><given-names>K</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS</article-title><source>Nat Genet</source><year>2002</year><volume>31</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">12134147</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Nelson</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Pellett</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wade</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>MJ</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name></person-group><article-title>Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>2818</fpage><lpage>2822</lpage><pub-id pub-id-type="pmid">12218090</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Linden</surname><given-names>S</given-names></name><name><surname>Valkenburg</surname><given-names>HA</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria</article-title><source>Arthritis Rheum</source><year>1984</year><volume>27</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">6231933</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Fern&#x000e1;ndez</surname><given-names>S</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S</given-names></name><name><surname>Mi&#x000f1;a Blanco</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez-Borra</surname><given-names>J</given-names></name><name><surname>Blanco-Gelaz</surname><given-names>MA</given-names></name><name><surname>L&#x000f3;pez-Vazquez</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Larrea</surname><given-names>C</given-names></name></person-group><article-title>New insights regarding HLA-B27 diversity in the Asian population</article-title><source>Tissue Antigens</source><year>2001</year><volume>58</volume><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11782278</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2001.580407.x</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Lozano</surname><given-names>N</given-names></name><name><surname>Vilches</surname><given-names>C</given-names></name></person-group><article-title>Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers. An update</article-title><source>Tissue Antigens</source><year>2002</year><volume>59</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">12074708</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2002.590302.x</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armas</surname><given-names>JB</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;nez-Borra</surname><given-names>J</given-names></name><name><surname>Laranjeira</surname><given-names>F</given-names></name><name><surname>Ribeiro</surname><given-names>E</given-names></name><name><surname>Correia</surname><given-names>J</given-names></name><name><surname>Ferreira</surname><given-names>ML</given-names></name><name><surname>Toste</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez-Vazquez</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Larrea</surname><given-names>C</given-names></name></person-group><article-title>Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles</article-title><source>Tissue Antigens</source><year>1999</year><volume>53</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">10203016</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.1999.530303.x</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>S</given-names></name><name><surname>Garc&#x000ed;a-Fernandez</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;nez-Borra</surname><given-names>J</given-names></name><name><surname>Blanco-Gel&#x000e1;z</surname><given-names>MA</given-names></name><name><surname>Rodr&#x000f3;go</surname><given-names>L</given-names></name><name><surname>Sanchez del R&#x000ed;o</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez-V&#x000e1;zquez</surname><given-names>A</given-names></name><name><surname>Torre-Alonso</surname><given-names>JC</given-names></name><name><surname>L&#x000f3;pez-Larrea</surname><given-names>C</given-names></name></person-group><article-title>High variability of HLA-B27 alleles in ankylosing spondylitis and related spondyloarthropathies in the population of northern Spain</article-title><source>Hum Immunol</source><year>2002</year><volume>63</volume><fpage>673</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">12121675</pub-id><pub-id pub-id-type="doi">10.1016/S0198-8859(02)00404-4</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pando</surname><given-names>MJ</given-names></name><name><surname>Gardiner</surname><given-names>CM</given-names></name><name><surname>Gleimer</surname><given-names>M</given-names></name><name><surname>McQueen</surname><given-names>KL</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>The protein made from a common allele of KIR 3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig Domain 0 and 182 in Ig Domain 1</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>6640</fpage><lpage>6649</lpage><pub-id pub-id-type="pmid">14662867</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>WH</given-names></name><name><surname>Pando</surname><given-names>MJ</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>5222</fpage><lpage>5229</lpage><pub-id pub-id-type="pmid">16210627</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Larrea</surname><given-names>C</given-names></name><name><surname>Segundo</surname><given-names>G</given-names></name><name><surname>Martinez-Borra</surname><given-names>J</given-names></name></person-group><article-title>The role of HLA-B27 polymorphism and molecular mimicry in spondyloarthropathy</article-title><source>Mol Med Today</source><year>1998</year><volume>4</volume><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">9866824</pub-id><pub-id pub-id-type="doi">10.1016/S1357-4310(98)01375-6</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollnberger</surname><given-names>S</given-names></name><name><surname>Bird</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>MY</given-names></name><name><surname>Retiere</surname><given-names>C</given-names></name><name><surname>Braud</surname><given-names>VM</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Bowness</surname><given-names>P</given-names></name></person-group><article-title>Cell-surface expression and immune receptor recognition of HLA-B27 homodimers</article-title><source>Arthritis Rheum</source><year>2002</year><volume>46</volume><fpage>2972</fpage><lpage>2982</lpage><pub-id pub-id-type="pmid">12428240</pub-id><pub-id pub-id-type="doi">10.1002/art.10605</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kollnberger</surname><given-names>S</given-names></name><name><surname>Bird</surname><given-names>LA</given-names></name><name><surname>Roddis</surname><given-names>M</given-names></name><name><surname>Hacquard-Bouder</surname><given-names>C</given-names></name><name><surname>Kubagawa</surname><given-names>H</given-names></name><name><surname>Bodmer</surname><given-names>HC</given-names></name><name><surname>Breban</surname><given-names>M</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Bowness</surname><given-names>P</given-names></name></person-group><article-title>HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>1699</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">15265899</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>H</given-names></name><name><surname>Kuon</surname><given-names>W</given-names></name><name><surname>Kuhne</surname><given-names>M</given-names></name><name><surname>Hulsmeyer</surname><given-names>M</given-names></name><name><surname>Kollnberger</surname><given-names>S</given-names></name><name><surname>Kuhlmann</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>E</given-names></name><name><surname>Zeitz</surname><given-names>M</given-names></name><name><surname>Wucherpfennig</surname><given-names>K</given-names></name><name><surname>Bowness</surname><given-names>P</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name></person-group><article-title>The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>6564</fpage><lpage>6573</lpage><pub-id pub-id-type="pmid">15557146</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liberatore</surname><given-names>C</given-names></name><name><surname>Capanni</surname><given-names>M</given-names></name><name><surname>Albi</surname><given-names>N</given-names></name><name><surname>Volpi</surname><given-names>I</given-names></name><name><surname>Urbani</surname><given-names>E</given-names></name><name><surname>Ruggeri</surname><given-names>L</given-names></name><name><surname>Mencarelli</surname><given-names>A</given-names></name><name><surname>Grignani</surname><given-names>F</given-names></name><name><surname>Velardi</surname><given-names>A</given-names></name></person-group><article-title>Natural killer cell-mediated lysis of autologous cells modified by gene therapy</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>1855</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">10377181</pub-id><pub-id pub-id-type="doi">10.1084/jem.189.12.1855</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart-Jones</surname><given-names>GB</given-names></name><name><surname>di Gleria</surname><given-names>K</given-names></name><name><surname>Kollnberger</surname><given-names>S</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name><name><surname>Bowness</surname><given-names>P</given-names></name></person-group><article-title>Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">15657948</pub-id><pub-id pub-id-type="doi">10.1002/eji.200425724</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>MR</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name></person-group><article-title>The double life of NK receptors: stimulation or co-stimulation?</article-title><source>Trends Immunol</source><year>2004</year><volume>25</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">14698281</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2003.10.011</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Namekawa</surname><given-names>T</given-names></name><name><surname>Snyder</surname><given-names>MR</given-names></name><name><surname>Yen</surname><given-names>JH</given-names></name><name><surname>Goehring</surname><given-names>BE</given-names></name><name><surname>Leibson</surname><given-names>PJ</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name></person-group><article-title>Killer cell activating receptors function as costimulatory molecules on CD4<sup>+</sup>CD28<sup>null </sup>T cells clonally expanded in rheumatoid arthritis</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>1138</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">10878393</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duftner</surname><given-names>C</given-names></name><name><surname>Goldberger</surname><given-names>C</given-names></name><name><surname>Falkenbach</surname><given-names>A</given-names></name><name><surname>Wurzner</surname><given-names>R</given-names></name><name><surname>Falkensammer</surname><given-names>B</given-names></name><name><surname>Pfeiffer</surname><given-names>KP</given-names></name><name><surname>Maerker-Hermann</surname><given-names>E</given-names></name><name><surname>Schirmer</surname><given-names>M</given-names></name></person-group><article-title>Prevalence, clinical relevance and characterization of circulating cytotoxic CD4<sup>+</sup>CD28<sup>- </sup>T cell in ankylosing spondylitis</article-title><source>Arthritis Res Ther</source><year>2003</year><volume>5</volume><fpage>R292</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">12932293</pub-id><pub-id pub-id-type="doi">10.1186/ar793</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schirmer</surname><given-names>M</given-names></name><name><surname>Goldberger</surname><given-names>C</given-names></name><name><surname>Wurzner</surname><given-names>R</given-names></name><name><surname>Duftner</surname><given-names>C</given-names></name><name><surname>Pfeiffer</surname><given-names>KP</given-names></name><name><surname>Clausen</surname><given-names>J</given-names></name><name><surname>Neumayr</surname><given-names>G</given-names></name><name><surname>Falkenbach</surname><given-names>A</given-names></name></person-group><article-title>Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis</article-title><source>Arthritis Res</source><year>2002</year><volume>4</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11879540</pub-id><pub-id pub-id-type="doi">10.1186/ar386</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>JH</given-names></name><name><surname>Moore</surname><given-names>BE</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Scholl</surname><given-names>D</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name></person-group><article-title>Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>1159</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">11369787</pub-id><pub-id pub-id-type="doi">10.1084/jem.193.10.1159</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>PB</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name><name><surname>Schaid</surname><given-names>D</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name></person-group><article-title>Expansion of unusual CD4<sup>+ </sup>T cells in severe rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><fpage>1106</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">9182921</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dulphy</surname><given-names>N</given-names></name><name><surname>Rabian</surname><given-names>C</given-names></name><name><surname>Douay</surname><given-names>C</given-names></name><name><surname>Flinois</surname><given-names>O</given-names></name><name><surname>Laoussadi</surname><given-names>S</given-names></name><name><surname>Kuipers</surname><given-names>J</given-names></name><name><surname>Tamouza</surname><given-names>R</given-names></name><name><surname>Charron</surname><given-names>D</given-names></name><name><surname>Toubert</surname><given-names>A</given-names></name></person-group><article-title>Functional modulation of expanded CD8<sup>+ </sup>synovial fluid T cells by NK cell receptor expression in HLA-B27-associated reactive arthritis</article-title><source>Int Immunol</source><year>2002</year><volume>14</volume><fpage>471</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">11978777</pub-id><pub-id pub-id-type="doi">10.1093/intimm/14.5.471</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Distribution of B27 subtypes in patients with ankylosing spondylitis (AS) and controls in Spanish and Azorian populations</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>Spanish</bold></td><td align="center" colspan="2"><bold>Azorian</bold></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td align="left">Subtypes</td><td align="center"><bold>Patients with AS (<italic>n </italic>= 71)</bold></td><td align="center"><bold>Controls (<italic>n </italic>= 105)</bold></td><td align="center"><bold>Patients with AS (<italic>n </italic>= 55)</bold></td><td align="center"><bold>Controls (<italic>n </italic>= 57)</bold></td></tr></thead><tbody><tr><td align="left">B*2705</td><td align="center">68 (95.7%)</td><td align="center">94 (89.5%)</td><td align="center">45 (81.8%)</td><td align="center">52 (91.2%)</td></tr><tr><td align="left">B*2702</td><td align="center">3 (4.3%)</td><td align="center">9 (8.6%)</td><td align="center">7 (12.7%)</td><td align="center">2 (3.5%)</td></tr><tr><td align="left">B*2703</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">2 (3.5%)</td></tr><tr><td align="left">B*2707</td><td align="center">-</td><td align="center">1 (0.95%)</td><td align="center">-</td><td align="center">1 (1.8%)</td></tr><tr><td align="left">B*2708</td><td align="center">-</td><td align="center">-</td><td align="center">3 (5.5%)</td><td align="center">-</td></tr><tr><td align="left">B*2713</td><td align="center">-</td><td align="center">1 (0.95%)</td><td align="center">-</td><td align="center">-</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Allelic and genotypic frequencies of KIR and HLA-B Bw4-I80 in patients with AS and B27 healthy controls in Spanish and Azorian populations.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Genotypes</td><td align="center"><bold>Spanish AS (2<italic>n </italic>= 142)</bold></td><td align="center"><bold>Spanish controls (2<italic>n </italic>= 210)</bold></td><td align="center"><bold><italic>p</italic></bold></td><td align="center"><bold>OR (95%CI)</bold></td><td align="center"><bold>Azorean AS (2<italic>n </italic>= 110)</bold></td><td align="center"><bold>Azorean controls (2<italic>n </italic>= 114)</bold></td><td align="center"><bold><italic>p</italic></bold></td><td align="center"><bold>OR (95%CI)</bold></td></tr></thead><tbody><tr><td align="left"><italic>3DS1</italic></td><td align="center">61 (42.9%)</td><td align="center">47 (22.3%)</td><td align="center">&#x0003c;0.0001</td><td align="center">2.6 (1.64&#x02013;4.15)</td><td align="center">39 (35.4%)</td><td align="center">20 (17.5%)</td><td align="center">&#x0003c;0.003</td><td align="center">2.58 (1.38&#x02013;4.8)</td></tr><tr><td align="left"><italic>3DL1</italic></td><td align="center">81 (57%)</td><td align="center">163 (77.6%)</td><td align="center">&#x0003c;0.0001</td><td align="center">0.3 (0.24&#x02013;0.6)</td><td align="center">71 (64.5%)</td><td align="center">94 (82.4%)</td><td align="center">&#x0003c;0.003</td><td align="center">0.38 (0.2&#x02013;0.72)</td></tr><tr><td align="left">Bw4I80</td><td align="center">24 (16.9%)</td><td align="center">40 (19%)</td><td align="center">NS</td><td align="center">-</td><td align="center">18 (16.3%)</td><td align="center">17 (14.9%)</td><td align="center">NS</td><td align="center">-</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Genotypes</td><td align="center"><bold>Spanish AS (<italic>n </italic>= 71)</bold></td><td align="center"><bold>Spanish controls (<italic>n </italic>= 105)</bold></td><td></td><td></td><td align="center"><bold>Azorean AS (<italic>n </italic>= 55)</bold></td><td align="center"><bold>Azorean controls (<italic>n </italic>= 57)</bold></td><td></td><td></td></tr><tr><td align="left"><italic>3DL1</italic>/<italic>3DL1</italic></td><td align="center">25 (35.2%)</td><td align="center">65 (61.9%)</td><td align="center">0.0008</td><td align="center">0.33 (0.17&#x02013;0.62)</td><td align="center">20 (36.3%)</td><td align="center">39 (68.4%)</td><td align="center">&#x0003c;0.001</td><td align="center">0.26 (0.12&#x02013;0.57)</td></tr><tr><td align="left"><italic>3DS1</italic>/<italic>3DS1</italic></td><td align="center">15 (21.1%)</td><td align="center">7 (6.6%)</td><td align="center">0.0009</td><td align="center">3.75 (1.44&#x02013;9.74)</td><td align="center">4 (7.2%)</td><td align="center">2 (3.5%)</td><td align="center">NS</td><td align="center">-</td></tr><tr><td align="left"><italic>3DS1</italic>/<italic>3DL1</italic></td><td align="center">31 (43.6%)</td><td align="center">33 (31.4%)</td><td align="center">NS</td><td align="center">-</td><td align="center">31 (56.1%)</td><td align="center">16 (28%)</td><td align="center">0.005</td><td align="center">3.3 (1.50&#x02013;7.26)</td></tr><tr><td align="left"><italic>3DS1</italic>/Bw4I80 +</td><td align="center">22 (30.9%)</td><td align="center">16 (15.2%)</td><td align="center">0.02</td><td align="center">2.49 (1.2&#x02013;5.19)</td><td align="center">15 (27.2%)</td><td align="center">5 (8.7%)</td><td align="center">0.01</td><td align="center">4.4 (1.48&#x02013;13.37)</td></tr><tr><td align="left"><italic>3DS1</italic>/Bw4I80 -</td><td align="center">24 (33.8%)</td><td align="center">24 (22.8%)</td><td align="center">NS</td><td align="center">-</td><td align="center">20 (36.3%)</td><td align="center">13 (22.8%)</td><td align="center">NS</td><td align="center">-</td></tr><tr><td align="left"><italic>3DL1</italic>/Bw4I80 +</td><td align="center">14 (19.7%)</td><td align="center">37 (35.2%)</td><td align="center">0.03</td><td align="center">0.45 (0.22&#x02013;0.91)</td><td align="center">9 (16.3%)</td><td align="center">16 (28%)</td><td align="center">NS</td><td align="center">-</td></tr><tr><td align="left"><italic>3DL1</italic>/Bw4I80 -</td><td align="center">42 (59.1%)</td><td align="center">61 (58.1%)</td><td align="center">NS</td><td align="center">-</td><td align="center">36 (64.4%)</td><td align="center">39 (68.4%)</td><td align="center">NS</td><td align="center">-</td></tr></tbody></table><table-wrap-foot><p>AS, ankylosing spondylitis; CI, confidence interval; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; NS, not significant; OR, odds ratio.</p></table-wrap-foot></table-wrap></sec></back></article> 